Unique ID issued by UMIN | UMIN000045409 |
---|---|
Receipt number | R000051849 |
Scientific Title | A study on the prevention of exacerbation of oral mucositis by early initiation of Episil oral liquid in hematopoietic stem cell transplant recipients and head and neck cancer patients |
Date of disclosure of the study information | 2021/09/07 |
Last modified on | 2025/03/11 16:51:19 |
A study on the prevention of exacerbation of oral mucositis by early initiation of Episil oral liquid in hematopoietic stem cell transplant recipients and head and neck cancer patients
A study on the prevention of exacerbation of oral mucositis by early initiation of Episil oral liquid
A study on the prevention of exacerbation of oral mucositis by early initiation of Episil oral liquid in hematopoietic stem cell transplant recipients and head and neck cancer patients
A study on prevention of oral mucositis exacerbation by early initiation of Episil oral liquid
Japan |
Head and neck cancer, Hematological malignancy
Hematology and clinical oncology | Oto-rhino-laryngology | Dental medicine |
Malignancy
NO
The aim of this study is to investigate the effect of early initiation of Episil Oral liquid on the prevention of exacerbation of oral mucositis in patients with hematopoietic stem cell transplantation and head and neck cancer.
Efficacy
Exploratory
Oral mucositis pain (every week from the start of treatment, up to 4 weeks from the end of treatment)
Severity of oral mucositis, Nutritional assessment, Eating Status Scale, Pain control, usability
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
Institution is not considered as adjustment factor.
2
Treatment
Device,equipment |
Use Episil after the detection of Grade 1 oral mucositis (CTCAE v.5)
Use Episil after the detection of Grade2 or higher oral mucositis (CTCAE v.5)
Not applicable |
Not applicable |
Male and Female
1) Hematopoietic stem cell transplant patients
2) Head and neck chemo-radiotherapy patients
1) Patients who need assistance in using Episil.
2) Patients with lesions including the central nervous system (CNS), or having confirmed/suspected of metastasis/invasion in the CNS
3) Patients using opioids for pain management prior to the start of Episil administration.
4) Patients with serious infections or complication.
5) Patients with known allergy to any of the ingredients in Episil.
6) Patients judged to be inappropriate by the investigator.
90
1st name | Koji |
Middle name | |
Last name | Satoh |
Fujita Health University
Department of Dentistry and Oral-maxillofacial Surgery, School of Medicine
470-1192
1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, Japan
0562-93-2210
kjsato@fujita-hu.ac.jp
1st name | Mutsumi |
Middle name | |
Last name | Yamakoshi |
Fujita Health University Hospital
Department of Dentistry and Oral-maxillofacial Surgery
470-1192
1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, Japan
0562-93-2210
yama-dh@fujita-hu.ac.jp
Fujita Health University
Self-funding costs
Self funding
Fujita Health University Institutional Research Board
1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, Japan
0562-93-2862
f-irb@fujita-hu.ac.jp
NO
2021 | Year | 09 | Month | 07 | Day |
Unpublished
18
No longer recruiting
2021 | Year | 08 | Month | 05 | Day |
2021 | Year | 08 | Month | 05 | Day |
2021 | Year | 08 | Month | 31 | Day |
2024 | Year | 03 | Month | 31 | Day |
2024 | Year | 03 | Month | 31 | Day |
2024 | Year | 05 | Month | 10 | Day |
2024 | Year | 05 | Month | 10 | Day |
2021 | Year | 09 | Month | 07 | Day |
2025 | Year | 03 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051849